Pagano L, Gallamini A, Trapè G, et al. NK/T-cell lymphomas “nasal type”: an Italian multicentric retrospective survey[J]. Ann Oncol, 2006, 17(5): 794-800.
[2]
You JY, Chi KH, Yang MH, et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK) /T-cell lymphoma: a single institute survey in Taiwan[J]. Ann Oncol, 2004, 15(4): 618-625.
[3]
Chim C, Ma S, Au SY, et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index[J]. Blood, 2004, 103(1): 216-221
[4]
Jaff ES, Harris NL, Chan JK, et al. Proposed world health organization classification of neoplastic diseases of hematopoietic and lymphoid tissues[J]. Am J Surg Pathol, 1997, 21(2): 114-121.
[5]
Chan JK. The new World Health Organization classification of the lymphomas: the past, the present and the future[J]. Hematol Oncol, 2001, 19(4): 129-150.
[6]
Murashige N, Kami M, Kishi Y, et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms[J]. Br J Haematol, 2005, 130(4): 561-567.
[7]
Chan JK, Sin VC, Wong KF, et al. Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm[J]. Blood, 1997, 89(12): 4501-4513.
[8]
Swerdlow SH, Campo E, Harris NL, et al. WHO classification of tumors of hematopoietic and lymphoid tissues[M]. 4th ed. Extranodal NK/T-cell lymphoma, nasal type. International agency for research on cancer. Lyon: 2008: 285-288.
[9]
Li YX, Coucke PA, Li JY, et al. Primary non-Hodgkin′s lymphoma of the nasal cavity: prognostic significance of paranasal extension and the role of radiotherapy and chemotherapy[J]. Cancer, 1998, 83(3): 449-456.
[10]
Ribrag V, Ell Hajj M, Janot F, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx[J]. Leukemia, 2001, 15(7): 1123-1126.
[11]
Li YX, Yao B, Jin J, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma[J]. J Clin Oncol, 2006, 24(1): 181-189.
[12]
Yong W, Zheng W, Zhu J, et al. Midline NK/T-cell lymphoma nasal-type: treatment outcome, the effect of L-asparaginase based regimen, and prognostic factors[J]. Hematol Oncol, 2006, 24(1): 28-32.
[13]
Kim S, Kim J, Choi BS. Treatment outcome of front-line systemic chemotherapy for localized extranodal NK/T cell lymphoma in nasal and upper aerodigestive tract[J]. Leuk Lymphoma, 2006, 47(7): 1265-1273.
[14]
Lee J, Kim WS, Park YH, et al. Nasal-type NK/T cell lymphoma: clinical features and treatment outcome[J]. Br J Cancer, 2005, 92(7): 1226-1230.
Okamura T, Kishimoto T, Inoue M, et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK cell lymphoproliferative disease[J]. Bone Marrow Transplant, 2003, 31(2): 105-111.
[17]
Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T-cell lymphoma[J].Adv Hematol, 2010, 2010: 1-12.
[18]
Lee J, Park YH, Kim WS, et al. Extranodal nasal type NK/T cell lymphoma: elucidating clinical prognostic factors for risk-based stratification of therapy[J]. Eur J Cancer, 2005, 41(10): 1402-1408.
[19]
Koizumi K, Fujmoto K, Haseyama Y, et al. Effective high-dose chemotherapy combined with CD34+-selected peripheral blood stem cell transplantation in a patient with ctaneous involvement of nasal NK/T-cell lymphoma[J]. Eur J Haemtol, 2004, 72(2): 140-144.
[20]
Yokoyama H, Yamada MF, Ishizawa K, et al. Successful treatment of advanced extranodal NK/T cell lymphoma with unrelated cord blood transplantation[J]. Tohoku J Exp Med, 2007, 211(4): 395-359.
[21]
Corradini P, Dodero A, Zallio F, et al. Graft-versus lymphoma effect in ralapsed peripheral T-cell non-Hodgkin′s lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells[J]. J Clin Oncol, 2004, 22(11): 2172-2176.
